339011-06-2 Usage
Molecular Structure
2-(Isopropylamino)-6-(trifluoromethyl)-4-pyrimidinol is a synthetic compound that is structurally similar to the natural nucleotide building blocks of DNA and RNA.
Biological Activity
It has potential biological activities that are still being researched.
Potential Use
It has been studied for its potential use in the treatment of diseases such as cancer, as well as for its effects on the central nervous system.
Promise as a drug candidate
It shows promise as a potential drug candidate for various applications in the fields of medicine and biotechnology.
Chemical Properties
The specific chemical properties of 2-(Isopropylamino)-6-(trifluoromethyl)-4-pyrimidinol are not provided in the material.
Research Status
Its properties and potential uses are still being researched.
Check Digit Verification of cas no
The CAS Registry Mumber 339011-06-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,9,0,1 and 1 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 339011-06:
(8*3)+(7*3)+(6*9)+(5*0)+(4*1)+(3*1)+(2*0)+(1*6)=112
112 % 10 = 2
So 339011-06-2 is a valid CAS Registry Number.
339011-06-2Relevant academic research and scientific papers
Synthesis of novel strobilurin-pyrimidine derivatives and their antiproliferative activity against human cancer cell lines
Chai, Baoshan,Wang, Shuyang,Yu, Wenquan,Li, Huichao,Song, Chuanjun,Xu, Ying,Liu, Changling,Chang, Junbiao
supporting information, p. 3505 - 3510 (2013/07/28)
A series of new strobilurin-pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds I and II. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (8f, IC50 = 2.2 nM and 11d, IC50 = 3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds I and II and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin-pyrimidine analogs as potential antitumor agents for the treatment of leukemia.
